r 31, 2006 2,209 63
Additional paid-in capital 126,490,647 -
Accumulated other comprehensive income 1,481,779 63,954
Accumulated deficit (87,402,551) (69,851,819)
Total stockholders' equity (deficit) 40,572,084 (69,787,802)
Total liabilities, convertible redeemable
preferred stock, and stockholders'
equity (deficit) $66,611,132 $14,767,504
PHARMATHENE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Year ended December 31,
2007 2006
Contract and grant revenue $14,624,595 $1,641,822
Other revenue 19,020 21,484
14,643,615 1,663,306
Operating expenses:
Research and development 16,559,670 7,259,359
General and administrative 13,882,023 8,453,941
Depreciation and amortization 705,370 483,646
Total operating expenses 31,147,063 16,196,946
Loss from operations (16,503,448) (14,533,640)
Other income (expense):
Interest income 1,122,565 289,606
Gain on extinguishment of debt 886,963 -
Interest expense (2,122,624) (538,948)
Change in market value of derivative
instruments 3,029,241 (350,405)
Total other income (expense) 2,916,145 (599,747)
Net loss (13,587,303) (
'/>"/>
SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.2.
Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court3.
PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services4.
Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA5.
PharmAthene to Present at the BIO CEO & Investor Conference 20086.
PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations7.
PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 20088.
PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference9.
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia10.
PharmAthene to Delay Release of Full Year 2007 Financial Results11.
PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008